TNF and cancer: Anti-tumor necrosis factor (TNF) α agents are not recommended in these patients, not only because of their potent immunosuppressive effects and risk of cancer progression, but also due to a lack of efficacy that may be explained by a different pathogenic mechanism, not directly dependent on TNF α [92,129].